Medicare drug price negotiation is almost upon us. The Inflation Reduction Act (IRA) mandates that the Centers for Medicare and Medicaid Services (CMS) implement a maximum fair price (MFP) for drug price negotiation beginning in 2026. How should CMS implement such a program given such a short timeline?
Senior Managing Director Dr. Jason Shafrin recently published an Health Affairs article that recommends a three-step approach to implementing the MFP that moves toward a drug pricing paradigm based on treatment value.
Key Contacts